Tackling the antibiotic innovation challenge
As the world still suffers from the impact of the COVID-19 pandemic with the global death toll now surpassing 500,000 deaths, we are also challenged to think about the 700,000 patients that die each and every year due to antimicrobial resistance (AMR).
AMR threatens decades of medical progress as existing antibiotics become less effective to these resistant bacteria. Its long term economic cost is predicted to be even bigger than that of COVID-19. Whilst COVID-19 caught us all ill prepared, AMR is something that is predictable as it is a widely recognised global health crisis.
The AMR Action Fund launched on 9 July by 23 leading pharmaceutical companies from the US, Europe and Japan is sending a clear message of the need and urgency of tackling the threat of AMR. The initiative aims to create a viable innovation ecosystem for antibiotic research and bring two to four innovative new antibiotics to the world by the end of the decade.